HRMY Q3 2022 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$117M+45.2% YoY

Gross Profit

$94M80.4% margin

Operating Income

$12M10.2% margin

Net Income

$88M75.0% margin

EPS (Diluted)

$1.44

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$55M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$643M

Total Liabilities

$300M

Stockholders' Equity

$344M

Cash & Equivalents

$261M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$81M	+45.2%
Gross Profit	$94M	$66M	+42.5%
Operating Income	$12M	$21M	-43.5%
Net Income	$88M	-$10M	+1014.2%

Geographic Segments

United States

$500M100%